公开(公告)号：US20240360519A1

公开(公告)日：2024-10-31

申请号：US18762467

申请日：2024-07-02

Applicant: BillionToOne, Inc.

Inventor： Patrick YE ,  David TSAO ,  Oguzhan ATAY

IPC: C12Q1/6886 ,  C12Q1/6806 ,  C12Q1/6869

CPC classification number: C12Q1/6886 ,  C12Q1/6869 ,  C12Q1/6806 ,  C12Q2600/112 ,  C12Q2600/154

Abstract: Methods to quantify methylation in a DNA sample include treating the sample to encode the presence or absence of DNA methylation, adding to the sample a set of synthetic molecules (e.g., quality control template (QCT) molecules), generating a co-amplification mixture, sequencing the co-amplification mixture, and determining a number of methylated molecules in the sample based on the number of methylated reads from the sample and a number of reads from the set of synthetic molecules.

公开(公告)号：US20240360513A1

公开(公告)日：2024-10-31

申请号：US18676626

申请日：2024-05-29

Applicant: University of Iowa Research Foundation

Inventor： Meeshanthini V. Dogan ,  Robert Philibert

IPC: C12Q1/6883

CPC classification number: C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/156

Abstract: Methods and compositions are provided for detecting a predisposition for cardiovascular disease in an individual.

公开(公告)号：US20240350460A1

公开(公告)日：2024-10-24

申请号：US18685925

申请日：2022-08-18

Applicant: NANJING SHIJIANG MEDICINE TECHNOLOGY CO., LTD

Inventor： Yufeng SHI ,  Wenjiang MA

IPC: A61K31/422 ,  A61K31/345 ,  A61P35/00 ,  C12Q1/6886

CPC classification number: A61K31/422 ,  A61K31/345 ,  A61P35/00 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.

公开(公告)号：US12123058B2

公开(公告)日：2024-10-22

申请号：US16963948

申请日：2019-01-25

Applicant: SORBONNE UNIVERSITE ,  CTRE RECHERCHE PATHOLOGIES PROSTATIQUES ,  LIGUE NATIONALE CONTRE LE CANCER ,  ASSISTANCE PUBLIQUE HOPITAUX DE PARIS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE TOURS ,  CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE TOURS

Inventor： Olivier Cussenot ,  Aurélie Kamoun ,  Aurélien De Reynies ,  Géraldine Cancel-Tassin ,  Gaëlle Fromont-Hankard

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158

Abstract: A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.

公开(公告)号：US20240336974A1

公开(公告)日：2024-10-10

申请号：US18430518

申请日：2024-02-01

Applicant: SELF-SCREEN B.V.

Inventor： Christophorus Joannes Lambertus Maria MEIJER ,  Renske Daniëla Maria STEENBERGEN ,  Petrus Josephus Ferdinandus SNIJDERS ,  Daniëlle Anne Marie HEIDEMAN

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/154

Abstract: The invention relates to method for detecting HPV-induced high-grade precancerous lesions, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers, said method comprising detection of a methylation classifier consisting of the genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in a cell whereby such hypermethylation indicates the presence of HPV-induced precursor lesions with invasive potential, HPV-induced invasive cancers and nonHPV-induced gynaecological and anogenital cancers. The invention further comprises the use of the methylation classifier consisting of genes LHX8, ASCL1 and ST6GALNAC5 and their regulatory sequence in such a method and a test kit for the detection of LHX8, ASCL1 and/or ST6GALNAC5 methylation.

公开(公告)号：US20240327922A1

公开(公告)日：2024-10-03

申请号：US18268240

申请日：2021-12-17

Applicant: Jiantao SHI ,  Zachary D. SMITH ,  Alexander MEISSNER ,  Franziska MICHOR ,  President and Fellows of Harvard College ,  DANA-FARBER CANCER INSTITUTE, INC.

Inventor： Jiantao Shi ,  Zachary D. Smith ,  Alexander Meissner ,  Franziska Michor

IPC: C12Q1/6886 ,  G16B20/10 ,  G16B40/20

CPC classification number: C12Q1/6886 ,  G16B20/10 ,  G16B40/20 ,  C12Q2600/154

Abstract: The present invention relates to methods of characterizing cell-free DNA (cfDNA), detecting cancer, detecting the eradication of cancer, and determining a probability distribution of haplotypes. The methods use the data from genomic sequences from CpG Islands (CGI) methylated in the genome of extraembryonic ectoderm (ExE) to determine a proportion of fully methylated haplotypes in order to characterize the cfDNA sample and detect certain cancers.

公开(公告)号：US20240309440A1

公开(公告)日：2024-09-19

申请号：US18434556

申请日：2024-02-06

Applicant: The Regents of the University of California

Inventor： Minnie M. Sarwal ,  Tara K. Sigdel ,  Joshua Y. Yang

IPC: C12Q1/6853 ,  C12Q1/6813 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/68 ,  G01N33/70 ,  G16H10/40

CPC classification number: C12Q1/6853 ,  C12Q1/6813 ,  C12Q1/6827 ,  C12Q1/6876 ,  C12Q1/6883 ,  G01N33/53 ,  G01N33/68 ,  G01N33/6827 ,  G01N33/6839 ,  G16H10/40 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/70 ,  G01N2800/245 ,  G01N2800/347

Abstract: This present disclosure provides methods and compositions that can be used to quantify cfDNA in biofluids using a hybridization approach.

公开(公告)号：US20240309426A1

公开(公告)日：2024-09-19

申请号：US18589016

申请日：2024-02-27

Applicant: Exact Sciences Cororation

Inventor： Hatim T. Allawi ,  Graham P. Lidgard ,  Brian Aizenstein ,  Melissa M. Gray

IPC: C12Q1/6806 ,  C12N15/10

CPC classification number: C12Q1/6806 ,  C12N15/1006 ,  C12Q2600/154 ,  C12Q2600/16

Abstract: The present invention provides synthetic DNA strands that find use as process controls in DNA processing and nucleic acid testing methods. In particular, provided herein are synthetic methylated DNA strands of known composition for use as control molecules in DNA testing, e.g., of mutations and/or methylation of DNA isolated from non-fish samples, such as human samples.

公开(公告)号：US20240304279A1

公开(公告)日：2024-09-12

申请号：US18646630

申请日：2024-04-25

Applicant: The Chinese University of Hong Kong

Inventor： Rossa Wai Kwun Chiu ,  Kwan Chee Chan ,  Yuk-Ming Dennis Lo ,  Peiyong Jiang ,  Kun Sun

IPC: G16B20/20 ,  C12Q1/6809 ,  C12Q1/689 ,  G16B20/00 ,  G16B20/10 ,  G16B30/00 ,  G16B30/10

CPC classification number: G16B20/20 ,  C12Q1/6809 ,  C12Q1/689 ,  G16B20/00 ,  G16B20/10 ,  G16B30/10 ,  C12Q2600/112 ,  C12Q2600/154 ,  G16B30/00

Abstract: The contributions of different tissues to a DNA mixture are determined using methylation levels at particular genomic sites. Tissue-specific methylation levels of M tissue types can be used to deconvolve mixture methylation levels measured in the DNA mixture, to determine fraction contributions of each of the M tissue types. Various types of genomic sites can be chosen to have particular properties across tissue types and across individuals, so as to provide increased accuracy in determining contributions of the various tissue types. The fractional contributions can be used to detect abnormal contributions of a particular tissue, indicating a disease state for the tissue. A differential in fractional contributions for different sizes of DNA fragments can also be used to identify a diseased state of a particular tissue. A sequence imbalance for a particular chromosomal region can be detected in a particular tissue, e.g., identifying a location of a tumor.

公开(公告)号：US20240301508A1

公开(公告)日：2024-09-12

申请号：US18674280

申请日：2024-05-24

Applicant: Quest Diagnostics Investments LLC

Inventor： Kevin Qu ,  Feras Hantash ,  Amber Donahue

IPC: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827

CPC classification number: C12Q1/6886 ,  C07K14/82 ,  C12N9/16 ,  C12Q1/6816 ,  C12Q1/6827 ,  C12Q2600/112 ,  C12Q2600/154 ,  C12Q2600/156 ,  C12Q2600/16

Abstract: The present technology relates to methods for excluding Lynch syndrome as a possible diagnosis in patients suffering from colorectal cancers or endometrial cancers. These methods are based on detecting the methylation status of the MLH1 promoter ‘C’ region in colorectal and endometrial cancer patients using an improved and highly sensitive methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) assay.